Erectile Dysfunction News and Research

Latest Erectile Dysfunction News and Research

Sex therapy for prostate cancer after treatment may improve sex life: Study

Prostate cancer treatments can play havoc with men’s sex lives causing erectile dysfunction and other frustrating problems. For example, a recent study found about 60 percent of men with prostate cancer who had their prostate glands removed had not recovered their sexual function two years after their treatment. Many also lost some desire for sex and had a diminished ability to reach or enjoy orgasms. But new research shows that sex therapy can make a big difference.

27 Sep 2011

Couples counseling can benefit prostate cancer patients' sex lives

Both internet-based counseling programs and face-to-face therapy sessions for couples improve the sex lives of prostate cancer survivors and their spouses. That is the finding of a new study published early online in Cancer, a peer-reviewed journal of the American Cancer Society.

26 Sep 2011

Prediction models may effectively identify erectile function after prostate cancer surgery

The development of prediction models that included variables such as pretreatment sexual function, patient characteristics and treatment factors appear to be effective at predicting erectile function 2 years after prostatectomy, external radiotherapy, or brachytherapy for prostate cancer, according to a study in the September 21 issue of JAMA.

21 Sep 2011

Multiple abstracts on QNEXA presented at 47th EASD

VIVUS, Inc. today announced that multiple abstracts were presented at the 47th European Association for the Study of Diabetes (EASD) Annual Meeting in Lisbon, Portugal. The presentations highlighted the long-term beneficial effects of QNEXA treatment in metabolically-impaired patients with prediabetes, diabetes, and metabolic syndrome.

17 Sep 2011

UIC researchers to conduct study on televised drug commercials

Do pharmaceutical ads educate patients and improve health -- or merely spur drug sales? Researchers at the University of Illinois at Chicago's Institute for Health Research and Policy will conduct the first comprehensive study of televised drug commercials using Nielsen Media Research and health care utilization data.

15 Sep 2011

VIVUS presents positive results from avanafil phase 3 study in diabetics at 47th EASD meeting

VIVUS, Inc. today presented positive results from the avanafil phase 3 study in diabetics. In the REVIVE-Diabetes study (TA-302), male diabetics receiving avanafil had significant improvement in erectile function.

14 Sep 2011

FDA’s response to Tobacco company’s allegations on graphic cigarette labels

The Food and Drug Administration (FDA) has replied to the claims from cigarette makers that new graphic-warning labels due to take effect next year violate tobacco companies’ free speech rights.

13 Sep 2011

Diamyd receives NIH grant to develop NTDDS for Chemotherapy Induced Peripheral Neuropathy

Diamyd Medical AB with collaborators has received a three million dollar grant from the US National Institutes of Health to develop the Company's patented Nerve Targeting Drug Delivery System (NTDDS) for prevention of Chemotherapy Induced Peripheral Neuropathy.

12 Sep 2011

Sagene completes SPI-1972 pre-IND meeting with FDA for erectile dysfunction

Sagene Pharmaceuticals, Inc., a biopharmaceutical company focused on developing combinations of FDA-approved drugs to treat diseases associated with aging, has completed a pre-IND meeting with the Division of Reproductive and Urologic Products of the FDA to discuss the development plan for SPI-1972, a dual-action combination treatment for erectile dysfunction.

9 Sep 2011

Health Canada approves Bayer's STAXYN for treatment of erectile dysfunction

Today, Bayer Inc. announced the Health Canada approval of STAXYN, the first orally disintegrating tablet for the treatment of erectile dysfunction (ED) that lasts up to eight hours.

29 Aug 2011

NovaDel, Rechon enter license and distribution agreement for Zolpimist

NovaDel Pharma Inc., a specialty pharmaceutical company that develops oral spray formulations of marketed pharmaceutical products, today announced its entry into an exclusive license and distribution agreement with Rechon Life Science AB to manufacture and commercialize Zolpimist® outside the United States and Canada. Zolpimist is our oral spray formulation of zolpidem tartrate approved by the FDA in December of 2008.

23 Aug 2011

New source for sexual problems in men – buddies!

Social researchers have found that there may be a new source for sexual problems among middle-aged and older men and it could be the relationships between their female partners and the men's closest friends.

12 Aug 2011

Researchers identify new source for sexual problems in middle-aged, older men

Researchers have found a potential new source for sexual problems among middle-aged and older men: the relationships between their female partners and the men's closest friends.

9 Aug 2011

Even minor weight loss can improve men’s sex lives: Study

The team of Australian researchers placed 31 obese men with type 2 diabetes on either a meal replacement-based low-calorie diet or a low-fat, high-protein, reduced-carbohydrate diet meant to decrease calorie intake by 600 calories a day. A modest weight loss of 5 percent led to an easing of erectile dysfunction and improved sexual desire within eight weeks, and these improvements continued for 12 months, according to the study published Aug. 5 in The Journal of Sexual Medicine. Problems with urinary tract function also improved, the team added.

8 Aug 2011

VIVUS announces additional data from phase 3 QNEXA studies on obesity

VIVUS, Inc. today announced that additional data from the phase 3 QNEXA studies will be presented today during the American Association of Diabetes Educators (AADE) meeting in Las Vegas, NV.

6 Aug 2011

Antioxidants may help treat infertility problems in both women and men

A growing body of evidence suggests that antioxidants may have significant value in addressing infertility issues in both women and men, including erectile dysfunction, and researchers say that large, specific clinical studies are merited to determine how much they could help.

29 Jul 2011

Nano-emulsion shows promise for Viagra patch

Sildenafil citrate, commonly known as Viagra, is currently the first choice drug for erectile dysfunction but despite its success oral delivery of the drug is hampered by numerous side effects, the long delay before it starts working and the short amount of time it lasts. Researchers in Egypt think they may have a solution via nanotechnology.

27 Jul 2011

VIVUS to present topiramate exposure, birth defect data at IEC

VIVUS, Inc. today announced that on August 31, 2011, during the late breaking poster session at the 29th International Epilepsy Congress in Rome, Italy, Dr. Alison Pack, Associate Professor of Clinical Neurology, Department of Neurology, Columbia University Medical Center, will present the results of a retrospective study of medical claims data on oral clefts (OC) and major congenital malformations (MCMs) associated with in utero topiramate exposure.

20 Jul 2011

Men with early-stage prostate cancer can benefit from short-term ADT, radiation therapy

Short-term hormone therapy given in combination with radiation therapy for men with early-stage prostate cancer increases their chance of living longer and not dying from the disease, compared with that of those who receive the same radiation therapy alone, according to a Radiation Therapy Oncology Group (RTOG) study published in the July 14 issue of the New England Journal of Medicine.

14 Jul 2011

VIVUS submits avanafil NDA to FDA for treatment of erectile dysfunction

VIVUS, Inc. today announced that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval of avanafil, its investigational drug for the treatment of erectile dysfunction.

30 Jun 2011